• Home
  • Congress & Events
  • APVRS 2024
  • Patient Preference for the Port Delivery System With Ranibizumab (PDS) vs Intravitreal Injections: 1-Year Results From the Phase 3 Pagoda Trial in Patients With Diabetic Macular Edema (DME)
Live

APVRS 2024

Nov 22 - Nov 24, 2024 | Singapore, Singapore

Share this page

Close Tooltip
Copy Link Tooltip

Copy page URL

Patient Preference for the Port Delivery System With Ranibizumab (PDS) vs Intravitreal Injections: 1-Year Results From the Phase 3 Pagoda Trial in Patients With Diabetic Macular Edema (DME)

Authors Koh A, Chang M, Marcus D, Baldonado K, Daly A, Tian K

Published date22 November, 2024

This presentation reports data supporting patient preference for the Port Delivery System with ranibizumab vs intravitreal injections in the phase 3 Pagoda trial for patients with DME at 1 year.

Download Current View

Welcome to Medically

The Roche Science Hub

This website is a non-promotional global resource intended to facilitate transparent scientific exchange regarding developments in medical research, diagnostics, and disease management. It is intended for healthcare professionals.

Not a healthcare professional? Browse:

This global website is intended for healthcare professionals outside the UK, US, Canada and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same.

You are Leaving Medically

By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.

You are Leaving the Global Medically Site

By following this link, you are being redirected to another Roche page.